{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:45:50Z","timestamp":1791999950890,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI128913"],"award-info":[{"award-number":["U19 AI128913"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"City of Hope PDDV Program COH04"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.<\/jats:p>","DOI":"10.1038\/s41467-020-19819-1","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T06:03:35Z","timestamp":1606716215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2921-5377","authenticated-orcid":false,"given":"Flavia","family":"Chiuppesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela d\u2019Alincourt","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonsuh","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Kha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Iniguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Kaltcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0750-0887","authenticated-orcid":false,"given":"Roman","family":"Levytskyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1998-3719","authenticated-orcid":false,"given":"Nancy D.","family":"Ebelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9085-8139","authenticated-orcid":false,"given":"Tae Hyuk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R.","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2891-7905","authenticated-orcid":false,"given":"Yuriy","family":"Shostak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3579-7083","authenticated-orcid":false,"given":"Don J.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7624-6734","authenticated-orcid":false,"given":"Felix","family":"Wussow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"19819_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","volume":"97","author":"A Volz","year":"2017","unstructured":"Volz, A. & Sutter, G. Modified Vaccinia Virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv. Virus Res. 97, 187\u2013243 (2017).","journal-title":"Adv. Virus Res."},{"key":"19819_CR2","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","volume":"31","author":"SC Gilbert","year":"2013","unstructured":"Gilbert, S. C. Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 31, 4241\u20134246 (2013).","journal-title":"Vaccine"},{"key":"19819_CR3","doi-asserted-by":"publisher","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","volume":"89","author":"G Sutter","year":"1992","unstructured":"Sutter, G. & Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 89, 10847\u201310851 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"19819_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1006\/viro.1998.9123","volume":"244","author":"G Antoine","year":"1998","unstructured":"Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365\u2013396 (1998).","journal-title":"Virology"},{"key":"19819_CR5","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1099\/vir.0.83156-0","volume":"88","author":"C Meisinger-Henschel","year":"2007","unstructured":"Meisinger-Henschel, C. et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol. 88, 3249\u20133259 (2007).","journal-title":"J. Gen. Virol."},{"key":"19819_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1006\/viro.1997.8845","volume":"238","author":"MW Carroll","year":"1997","unstructured":"Carroll, M. W. & Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238, 198\u2013211 (1997).","journal-title":"Virology"},{"key":"19819_CR7","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","volume":"31","author":"MG Cottingham","year":"2013","unstructured":"Cottingham, M. G. & Carroll, M. W. Recombinant MVA vaccines: dispelling the myths. Vaccine 31, 4247\u20134251 (2013).","journal-title":"Vaccine"},{"key":"19819_CR8","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1128\/JVI.01669-12","volume":"87","author":"F Wussow","year":"2013","unstructured":"Wussow, F. et al. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J. Virol. 87, 1322\u20131332 (2013).","journal-title":"J. Virol."},{"key":"19819_CR9","doi-asserted-by":"publisher","first-page":"e1004524","DOI":"10.1371\/journal.ppat.1004524","volume":"10","author":"F Wussow","year":"2014","unstructured":"Wussow, F. et al. Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex. PLoS Pathog. 10, e1004524 (2014).","journal-title":"PLoS Pathog."},{"key":"19819_CR10","doi-asserted-by":"crossref","unstructured":"Chiuppesi, F. et al. Multiantigenic Modified Vaccinia Virus Ankara vaccine vectors to elicit potent humoral and cellular immune reponses against human cytomegalovirus in mice. J. Virol. 92, JVI.01012-18 (2018).","DOI":"10.1128\/JVI.01012-18"},{"key":"19819_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","volume":"129","author":"C La Rosa","year":"2017","unstructured":"La Rosa, C. et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood 129, 114\u2013125 (2017).","journal-title":"Blood"},{"key":"19819_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/M19-2511","volume":"172","author":"I Aldoss","year":"2020","unstructured":"Aldoss, I. et al. Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial. Ann. Intern. Med. 172, 306\u2013316 (2020).","journal-title":"Ann. Intern. Med."},{"key":"19819_CR13","doi-asserted-by":"publisher","first-page":"e1363138","DOI":"10.1080\/2162402X.2017.1363138","volume":"6","author":"Y Yuan","year":"2017","unstructured":"Yuan, Y. et al. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. Oncoimmunology 6, e1363138 (2017).","journal-title":"Oncoimmunology"},{"key":"19819_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"19819_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"19819_CR16","doi-asserted-by":"crossref","unstructured":"Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 382, 1969\u20131973 (2020).","DOI":"10.1056\/NEJMp2005630"},{"key":"19819_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16505-0","volume":"11","author":"TRF Smith","year":"2020","unstructured":"Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).","journal-title":"Nat. Commun."},{"key":"19819_CR18","doi-asserted-by":"crossref","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","DOI":"10.1126\/science.abc6284"},{"key":"19819_CR19","doi-asserted-by":"crossref","unstructured":"Zhu, F. -C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020).","DOI":"10.1016\/S0140-6736(20)31208-3"},{"key":"19819_CR20","doi-asserted-by":"crossref","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971\u2013977.e3 (2020).","DOI":"10.1016\/j.immuni.2020.04.023"},{"key":"19819_CR21","unstructured":"Long, Q. -X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020)."},{"key":"19819_CR22","unstructured":"Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020)."},{"key":"19819_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e278 (2020).","journal-title":"Cell"},{"key":"19819_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292.e286 (2020).","journal-title":"Cell"},{"key":"19819_CR25","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"19819_CR26","doi-asserted-by":"crossref","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e15 (2020).","DOI":"10.1016\/j.cell.2020.05.015"},{"key":"19819_CR27","unstructured":"Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020)."},{"key":"19819_CR28","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1128\/JVI.64.10.5029-5035.1990","volume":"64","author":"M Merchlinsky","year":"1990","unstructured":"Merchlinsky, M. Mutational analysis of the resolution sequence of vaccinia virus DNA: essential sequence consists of two separate AT-rich regions highly conserved among poxviruses. J. Virol. 64, 5029\u20135035 (1990).","journal-title":"J. Virol."},{"key":"19819_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1101\/SQB.1983.047.01.083","volume":"47","author":"BM Baroudy","year":"1983","unstructured":"Baroudy, B. M., Venkatesan, S. & Moss, B. Structure and replication of vaccinia virus telomeres. Cold Spring Harb. Symp. Quant. Biol. 47, 723\u2013729 (1983).","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"19819_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1128\/JVI.59.2.249-259.1986","volume":"59","author":"AM DeLange","year":"1986","unstructured":"DeLange, A. M., Reddy, M., Scraba, D., Upton, C. & McFadden, G. Replication and resolution of cloned poxvirus telomeres in vivo generates linear minichromosomes with intact viral hairpin termini. J. Virol. 59, 249\u2013259 (1986).","journal-title":"J. Virol."},{"key":"19819_CR31","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1128\/JVI.61.6.1957-1963.1987","volume":"61","author":"AM DeLange","year":"1987","unstructured":"DeLange, A. M. & McFadden, G. Efficient resolution of replicated poxvirus telomeres to native hairpin structures requires two inverted symmetrical copies of a core target DNA sequence. J. Virol. 61, 1957\u20131963 (1987).","journal-title":"J. Virol."},{"key":"19819_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0022-2836(88)90613-4","volume":"199","author":"M Merchlinsky","year":"1988","unstructured":"Merchlinsky, M., Garon, C. F. & Moss, B. Molecular cloning and sequence of the concatemer junction from vaccinia virus replicative DNA. Viral nuclease cleavage sites in cruciform structures. J. Mol. Biol. 199, 399\u2013413 (1988).","journal-title":"J. Mol. Biol."},{"key":"19819_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/0092-8674(86)90562-3","volume":"45","author":"M Merchlinsky","year":"1986","unstructured":"Merchlinsky, M. & Moss, B. Resolution of linear minichromosomes with hairpin ends from circular plasmids containing vaccinia virus concatemer junctions. Cell 45, 879\u2013884 (1986).","journal-title":"Cell"},{"key":"19819_CR34","doi-asserted-by":"publisher","first-page":"e1638","DOI":"10.1371\/journal.pone.0001638","volume":"3","author":"MG Cottingham","year":"2008","unstructured":"Cottingham, M. G. et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 3, e1638 (2008).","journal-title":"PLoS ONE"},{"key":"19819_CR35","doi-asserted-by":"publisher","first-page":"9977","DOI":"10.1073\/pnas.89.21.9977","volume":"89","author":"F Scheiflinger","year":"1992","unstructured":"Scheiflinger, F., Dorner, F. & Falkner, F. G. Construction of chimeric vaccinia viruses by molecular cloning and packaging. Proc. Natl Acad. Sci. USA 89, 9977\u20139981 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"19819_CR36","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/0264-410X(88)90101-6","volume":"6","author":"J Taylor","year":"1988","unstructured":"Taylor, J., Weinberg, R., Kawaoka, Y., Webster, R. G. & Paoletti, E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 6, 504\u2013508 (1988).","journal-title":"Vaccine"},{"key":"19819_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1439-0450.1966.tb00871.x","volume":"13","author":"A Mayr","year":"1966","unstructured":"Mayr, A. & Malicki, K. [Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus]. Zentralbl. Veterinarmed. B 13, 1\u201313 (1966).","journal-title":"Zentralbl. Veterinarmed. B"},{"key":"19819_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1084\/jem.20041912","volume":"201","author":"DC Tscharke","year":"2005","unstructured":"Tscharke, D. C. et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201, 95\u2013104 (2005).","journal-title":"J. Exp. Med."},{"key":"19819_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2144\/000112096","volume":"40","author":"BK Tischer","year":"2006","unstructured":"Tischer, B. K., von Einem, J., Kaufer, B. & Osterrieder, N. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40, 191\u2013197 (2006).","journal-title":"Biotechniques"},{"key":"19819_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/978-1-60761-652-8_30","volume":"634","author":"BK Tischer","year":"2010","unstructured":"Tischer, B. K., Smith, G. A. & Osterrieder, N. En passant mutagenesis: a two step markerless red recombination system. Methods Mol. Biol. 634, 421\u2013430 (2010).","journal-title":"Methods Mol. Biol."},{"key":"19819_CR41","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1128\/JVI.00687-09","volume":"83","author":"LS Wyatt","year":"2009","unstructured":"Wyatt, L. S. et al. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J. Virol. 83, 7176\u20137184 (2009).","journal-title":"J. Virol."},{"key":"19819_CR42","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0264-410X(96)00072-2","volume":"14","author":"LS Wyatt","year":"1996","unstructured":"Wyatt, L. S., Shors, S. T., Murphy, B. R. & Moss, B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14, 1451\u20131458 (1996).","journal-title":"Vaccine"},{"key":"19819_CR43","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.vaccine.2009.11.056","volume":"28","author":"Z Wang","year":"2010","unstructured":"Wang, Z. et al. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 28, 1547\u20131557 (2010).","journal-title":"Vaccine"},{"key":"19819_CR44","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1128\/JVI.00671-11","volume":"85","author":"M Jaume","year":"2011","unstructured":"Jaume, M. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. J. Virol. 85, 10582\u201310597 (2011).","journal-title":"J. Virol."},{"key":"19819_CR45","doi-asserted-by":"publisher","first-page":"e0188453","DOI":"10.1371\/journal.pone.0188453","volume":"13","author":"RS Noyce","year":"2018","unstructured":"Noyce, R. S., Lederman, S. & Evans, D. H. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS ONE 13, e0188453 (2018).","journal-title":"PLoS ONE"},{"key":"19819_CR46","doi-asserted-by":"crossref","unstructured":"Dutta, N. K., Mazumdar, K. & Gordy, J. T. The nucleocapsid protein of SARS-CoV-2: a target for vaccine development. J. Virol. 94, e00647-20 (2020).","DOI":"10.1128\/JVI.00647-20"},{"key":"19819_CR47","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","volume":"20","author":"A Iwasaki","year":"2020","unstructured":"Iwasaki, A. & Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 20, 339\u2013341 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"19819_CR48","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.abb8923","volume":"368","author":"BS Graham","year":"2020","unstructured":"Graham, B. S. Rapid COVID-19 vaccine development. Science 368, 945\u2013946 (2020).","journal-title":"Science"},{"key":"19819_CR49","doi-asserted-by":"publisher","first-page":"102768","DOI":"10.1016\/j.ebiom.2020.102768","volume":"55","author":"R de Alwis","year":"2020","unstructured":"de Alwis, R., Chen, S., Gan, E. S. & Ooi, E. E. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine 55, 102768 (2020).","journal-title":"EBioMedicine"},{"key":"19819_CR50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2355-0","volume":"583","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Viral and host factors related to the clinical outcome of COVID-19. Nature 583, 437\u2013440 (2020).","journal-title":"Nature"},{"key":"19819_CR51","doi-asserted-by":"crossref","unstructured":"Vabret, N. Antibody responses to SARS-CoV-2 short-lived. Nat. Rev. Immunol. 20, 519 (2020).","DOI":"10.1038\/s41577-020-0405-3"},{"key":"19819_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"N Le Bert","year":"2020","unstructured":"Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457\u2013462 (2020).","journal-title":"Nature"},{"key":"19819_CR53","doi-asserted-by":"crossref","unstructured":"Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12, 513 (2020).","DOI":"10.3390\/v12050513"},{"key":"19819_CR54","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1128\/JVI.78.8.3965-3976.2004","volume":"78","author":"Z Wang","year":"2004","unstructured":"Wang, Z. et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol. 78, 3965\u20133976 (2004).","journal-title":"J. Virol."},{"key":"19819_CR55","doi-asserted-by":"crossref","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963 (2020).","DOI":"10.1126\/science.abc7520"},{"key":"19819_CR56","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1093\/nar\/7.6.1513","volume":"7","author":"HC Birnboim","year":"1979","unstructured":"Birnboim, H. C. & Doly, J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7, 1513\u20131523 (1979).","journal-title":"Nucleic Acids Res."},{"key":"19819_CR57","first-page":"16.17.11","volume":"43","author":"PL Earl","year":"1998","unstructured":"Earl, P. L., Moss, B., Wyatt, L. S. & Carroll, M. W. Generation of recombinant Vaccinia viruses. Curr. Protoc. Mol. Biol. 43, 16.17.11\u201316.17.19 (1998).","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"19819_CR58","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1128\/JVI.68.1.130-147.1994","volume":"68","author":"M Schmelz","year":"1994","unstructured":"Schmelz, M. et al. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J. Virol. 68, 130\u2013147 (1994).","journal-title":"J. Virol."},{"key":"19819_CR59","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/dxg073","volume":"15","author":"PS Rohrlich","year":"2003","unstructured":"Rohrlich, P. S. et al. HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int. Immunol. 15, 765\u2013772 (2003).","journal-title":"Int. Immunol."},{"key":"19819_CR60","doi-asserted-by":"publisher","unstructured":"Millet, J. K. et al. Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting. J. Vis. Exp. https:\/\/doi.org\/10.3791\/59010 (2019).","DOI":"10.3791\/59010"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19819-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:49:10Z","timestamp":1670273350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19819-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["19819"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-19819-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-40198\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"5 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funds were allocated to Don J. Diamond by the City of Hope (COH) for research that resulted in the development of multi-antigenic SARS-CoV-2 vaccine using a synthetic poxvirus platform discussed in this publication. While unknown whether publication of this report will aid in receiving grants and contracts, it is possible that this publication will be of benefit to COH. COH had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. Don J. Diamond is a co-inventor on two patent applications that were submitted by COH to the USPTO prior to submission of this manuscript for consideration at Nature Communications. Both patent applications are in provisional status and have not yet converted to utility applications that have an official USPTO application number. One patent application covers the design and construction of the synthetic MVA platform, and another patent application covers the development of a COVID-19 vaccine. Felix Wussow is a co-inventor of the same two provisional patent applications that apply to Don J. Diamond. All remaining authors that have not been referenced above have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the interpretation of the article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6121"}}